Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
6 competitors in Duchenne Muscular Dystrophy
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Agamree
Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.